Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Bedognetti, Davide ^a   Wang, Ena ^a,b   Marincola, Francesco M ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Biomarkers; Breast cancer; CXCL 13; gene signature; Gene expression; Immunotherapy; Melanoma; Neoadjuvant chemotherapy

Indexed keywords

CXCL13 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; TRANSCRIPTOME;

APOPTOSIS; AUTOIMMUNITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CXCL13 GENE; DISEASE ASSOCIATION; EDITORIAL; ENDOPLASMIC RETICULUM STRESS; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; IMMUNE RESPONSE; MARKER GENE; PREDICTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84902579138     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28727     Document Type: Editorial

References (22)

1. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang E, Marincola FM, et al. Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 2011; 9:174; PMID:21992116; http://dx.doi.org/10.1186/1479-5876-9-174
2. Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010, 9, 555-65. PMID:20518712;http://dx.doi. org/10.1586/erv.10.55
3. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance:prognostic, predictive, and mechanistic signatures. Immunity 2013, 39, 11-26. PMID:23890060;http:// dx.doi.org/10.1016/j.immuni.2013.07.008
4. Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013, 31, 2369-71. PMID:23715576;http://dx.doi.org/10.1200/ JCO.2013.49.2157
5. Weiss GR, Grosh WW, Chianese-Bullock KA, Zhao Y, Liu H, Slingluff CL Jr., Marincola FM, Wang E. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011, 17, 7440-50. PMID:21976537;http://dx.doi.org/10.1158/1078-0432.CCR-11-1650
6. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61, 1019-31. PMID:22146893;http://dx.doi.org/10.1007/ s00262-011-1172-6
7. Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 2013, 109, 2412-23. PMID:24129241;http://dx.doi. org/10.1038/bjc.2013.557
8. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012, 1, 28-37. PMID:22720209;http://dx.doi. org/10.4161/onci.1.1.17938
9. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi. org/10.1126/scitranslmed.3003689
10. Tomei S, Wang E, Delogu LG, Marincola FM, Bedognetti D. Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opin Biol Ther 2014; (Forthcoming); PMID:24625306; http://dx.doi.org/10.1517/14712598.2014.890586
11. Pescatori M, Bedognetti D, Venturelli E, Ménard-Moyon C, Bernardini C, Muresu E, Piana A, Maida G, Manetti R, Sgarrella F, et al. Functionalized carbon nanotubes as immunomodulator systems. Biomaterials 2013, 34, 4395-403. PMID:23507086;http://dx.doi.org/10.1016/j.biomaterials.2013.02.052
12. Stoll G, Enot D, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. OncoImmunology 2014; 3:e27884
13. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013, 39, 74-88. PMID:23890065;http://dx.doi.org/10.1016/j.immuni.2013.06.014
14. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012, 1, 179-88. PMID:22720239;http://dx.doi.org/10.4161/ onci.1.2.19026
15. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012, 30, 1996-2004. PMID:22508827;http://dx.doi.org/10.1200/ JCO.2011.39.5624
16. Issa-Nummer Y, Loibl S, von Minckwitz G, Denkert C. Tumor-infiltrating lymphocytes in breast cancer:A new predictor for responses to therapy. OncoImmunology 2014; 3:e27926
17. + follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013, 123, 2873-92. PMID:23778140;http:// dx.doi.org/10.1172/JCI67428
18. Gu-Trantien C, Willard-Gallo K. Tumorinfiltrating follicular helper T cells: The new kids on the block. Oncoimmunology 2013; 2:e26066; PMID:24244900; http://dx.doi.org/10.4161/ onci.26066
19. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39, 782-95. PMID:24138885;http://dx.doi.org/10.1016/j. immuni.2013.10.003
20. Goc J, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2013; 2:e26836; PMID:24498556; http://dx.doi. org/10.4161/onci.26836
21. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013, 342, 967-70. PMID:24264989;http://dx.doi.org/10.1126/ science.1240527
22. Wang E, Bedognetti D, Tomei S, Marincola FM. Common pathways to tumor rejection. Ann N Y Acad Sci 2013; 1284:75-9; PMID:23651198; http://dx.doi.org/10.1111/nyas.12063